| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.1 | 0.04 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.1 | 0.04 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.074 | 0.04 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | -0.073 | 0.04 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.04 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.07 | 0.04 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.096 | 0.04 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.068 | 0.04 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.04 |